Impact of nivolumab vs standard, single-agent therapy of investigator’s choice on patient-reported outcomes in recurrent or metastatic squamous cell carcinoma of the head and neck: health-related quality-of-life results from CheckMate 141, a randomized, phase 3 trial

BACKGROUND: Patients with platinum-refractory recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) have limited treatment options and poor prognosis. Nivolumab significantly improved survival of this patient population when compared with standard single-agent therapy of...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Lancet Oncol
Prif Awduron: Harrington, Kevin J, Ferris, Robert L, Blumenschein, George, Colevas, A Dimitrios, Fayette, Jerome, Licitra, Lisa, Kasper, Stefan, Even, Caroline, Vokes, Everett E, Worden, Francis, Saba, Nabil F, Kiyota, Naomi, Haddad, Robert, Tahara, Makoto, Grünwald, Viktor, Shaw, James W, Monga, Manish, Lynch, Mark, Taylor, Fiona, DeRosa, Michael, Morrissey, Laura, Cocks, Kim, Gillison, Maura L, Guigay, Joel
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2017
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6461049/
https://ncbi.nlm.nih.gov/pubmed/28651929
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(17)30421-7
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg